Levy Health has raised $4.5 million in seed funding to further develop its clinical decision support platform for fertility diagnosis. The round was led by XYZ Ventures, with participation from Atlantic Labs and Possible Ventures.
Founded in 2022 by Caroline Mitterdorfer, Silvia Hecher, and Dr. Theresa Vilsmaier, Levy Health aims to speed up the process of diagnosing fertility issues in women. The company’s platform analyzes patient questionnaires, biomarkers, and lab work to narrow down potential diagnoses from a list of 110 conditions, presenting this information to doctors before patient consultations.
Levy Health reports that its process has led to a 50% reduction in time to diagnosis. The company currently has six B2B customers, including Progyny, Boston IVF, and Everie.
The startup plans to use the new funds to expand its team, enhance its technology, and fund clinical studies related to fertility and egg freezing. Levy Health is particularly focused on publishing a clinical study over the next six months to validate its key performance indicators in clinical support for women freezing their eggs.
Caroline Mitterdorfer, CEO of Levy Health, shared with TechCrunch: “For me, it is just critical to know that what we are building is helping, at the end of the day, hopefully millions of getting an early diagnosis.”
